|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu K, Zhao T, Wang J, Chen Y, Zhang R,
Lan X and Que J: Etiology, cancer stem cells and potential
diagnostic biomarkers for esophageal cancer. Cancer Lett.
458:21–28. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Y, Yin D, Li L, Deng YC and Tian W:
Screening aberrant methylation profile in esophageal squamous cell
carcinoma for Kazakhs in Xinjiang area of China. Mol Biol Rep.
42:457–464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang VE, Grandis JR and Ko AH: New
strategies in esophageal carcinoma: Translational insights from
signaling pathway and immune checkpoints. Clin Cancer Res.
22:4283–4290. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lowther WT and Matthews BW:
Metalloaminopeptidases: Common functional themes in disparate
structural surroundings. Chem Rev. 102:4581–4608. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saghatelian A, Jessani N, Joseph A,
Humphrey M and Cravatt BF: Activity-based probes for the proteomic
profiling of metalloproteases. Proc Natl Acad Sci USA.
101:10000–10005. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cerdà-Costa N and Gomis-Rüth FX:
Architecture and function of metallopeptidase catalytic domains.
Protein Sci. 23:123–144. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Menale C, Robinson LJ, Palagano E, Rigoni
R, Erreni M, Almarza AJ, Strina D, Mantero S, Lizier M, Forlino A,
et al: Absence of dipeptidyl peptidase 3 increases oxidative stress
and causes bone loss. J Bone Miner Res. 34:2133–2148. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jha S, Taschler U, Domenig O, Poglitsch M,
Bourgeois B, Pollheimer M, Pusch LM, Malovan G, Frank S, Madl T, et
al: Dipeptidyl peptidase 3 modulates the renin-angiotensin system
in mice. J Biol Chem. 295:13711–13723. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu K, Alcivar AL, Ma J, Foo TK, Zywea S,
Mahdi A, Huo Y, Kensler TW, Gatza ML and Xia B: NRF2 induction
supporting breast cancer cell survival is enabled by oxidative
stress-induced DPP3-KEAP1 interaction. Cancer Res. 77:2881–2892.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hast BE, Goldfarb D, Mulvaney KM, Hast MA,
Siesser PF, Yan F, Hayes DN and Major MB: Proteomic analysis of
ubiquitin ligase KEAP1 reveals associated proteins that inhibit
NRF2 ubiquitination. Cancer Res. 73:2199–2210. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Simaga S, Babić D, Osmak M, Ilić-Forko J,
Vitale L, Milicić D and Abramić M: Dipeptidyl peptidase III in
malignant and non-malignant gynaecological tissue. Eur J Cancer.
34:399–405. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Simaga S, Babić D, Osmak M, Sprem M and
Abramić M: Tumor cytosol dipeptidyl peptidase III activity is
increased with histological aggressiveness of ovarian primary
carcinomas. Gynecol Oncol. 91:194–200. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Singh R, Sharma MC, Sarkar C, Singh M and
Chauhan SS: Transcription factor C/EBP-β mediates downregulation of
dipeptidyl-peptidase III expression by interleukin-6 in human
glioblastoma cells. FEBS J. 281:1629–1641. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Prajapati SC and Chauhan SS: Human
dipeptidyl peptidase III mRNA variant I and II are expressed
concurrently in multiple tumor derived cell lines and translated at
comparable efficiency in vitro. Mol Biol Rep. 43:457–462. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Couto M and Cates C: Laboratory guidelines
for animal care. Methods Mol Biol. 1920:407–430. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mulvihill EE and Drucker DJ: Pharmacology,
physiology, and mechanisms of action of dipeptidyl peptidase-4
inhibitors. Endocr Rev. 35:992–1019. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sato A and Ogita H: Pathophysiological
implications of dipeptidyl peptidases. Curr Protein Pept Sci.
18:843–849. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tong Y, Huang Y, Zhang Y, Zeng X, Yan M,
Xia Z and Lai D: DPP3/CDK1 contributes to the progression of
colorectal cancer through regulating cell proliferation, cell
apoptosis, and cell migration. Cell Death Dis. 12:5292021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ren X, Yu J, Guo L and Ma H:
Dipeptidyl-peptidase 3 protects oxygen-glucose
deprivation/reoxygenation-injured hippocampal neurons by
suppressing apoptosis, oxidative stress and inflammation via
modulation of Keap1/Nrf2 signaling. Int Immunopharmacol.
96:1075952021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu X, Chen S, Xie C, Li Z, Wu Z and You Z:
DPP4 gene silencing inhibits proliferation and
epithelial-mesenchymal transition of papillary thyroid carcinoma
cells through suppression of the MAPK pathway. J Endocrinol Invest.
44:1609–1623. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ohnson DC, Taabazuing CY, Okondo MC, Chui
AJ, Rao SD, Brown FC, Reed C, Peguero E, de Stanchina E, Kentsis A
and Bachovchin DA: DPP8/DPP9 inhibitor-induced pyroptosis for
treatment of acute myeloid leukemia. Nat Med. 24:1151–1156. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Taabazuing CY, Okondo MC and Bachovchin
DA: Pyroptosis and apoptosis pathways engage in bidirectional
crosstalk in monocytes and macrophages. Cell Chem Biol.
24:507–514.e4. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cui C, Tian X, Wei L, Wang Y, Wang K and
Fu R: New insights into the role of dipeptidyl peptidase 8 and
dipeptidyl peptidase 9 and their inhibitors. Front Pharmacol.
13:10028712022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xie Y, Zhu S, Song X, Sun X, Fan Y, Liu J,
Zhong M, Yuan H, Zhang L, Billiar TR, et al: The tumor suppressor
p53 limits ferroptosis by blocking DPP4 activity. Cell Rep.
20:1692–1704. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Prajapati SC and Chauhan SS: Dipeptidyl
peptidase III: A multifaceted oligopeptide N-end cutter. FEBS J.
278:3256–3276. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vanha-Perttula T: Dipeptidyl peptidase III
and alanyl aminopeptidase in the human seminal plasma: Origin and
biochemical properties. Clin Chim Acta. 177:179–195. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shimamori Y, Watanabe Y and Fujimoto Y:
Purification and characterization of dipeptidyl aminopeptidase III
from human placenta. Chem Pharm Bull (Tokyo). 34:3333–3340. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Groblewska M, Siewko M, Mroczko B and
Szmitkowski M: The role of matrix metalloproteinases (MMPs) and
their inhibitors (TIMPs) in the development of esophageal cancer.
Folia Histochem Cytobiol. 50:12–19. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hashimoto J, Yamamoto Y, Kurosawa H,
Nishimura K and Hazato T: Identification of dipeptidyl peptidase
III in human neutrophils. Biochem Biophys Res Commun. 273:393–397.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mazzocco C, Fukasawa KM, Raymond AA and
Puiroux J: Purification, partial sequencing and characterization of
an insect membrane dipeptidyl aminopeptidase that degrades the
insect neuropeptide proctolin. Eur J Biochem. 268:4940–4949. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Choy TK, Wang CY, Phan NN, Khoa Ta HD,
Anuraga G, Liu YH, Wu YF, Lee KH, Chuang JY and Kao TJ:
Identification of dipeptidyl peptidase (DPP) family genes in
clinical breast cancer patients via an integrated bioinformatics
approach. Diagnostics (Basel). 11:12042021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gamrekelashvili J, Kapanadze T, Han M,
Wissing J, Ma C, Jaensch L, Manns MP, Armstrong T, Jaffee E, White
AO, et al: Peptidases released by necrotic cells control CD8+ T
cell cross-priming. J Clin Invest. 123:4755–4768. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu Y, Kern JT, Walker JR, Johnson JA,
Schultz PG and Luesch H: A genomic screen for activators of the
antioxidant response element. Proc. Natl Acad Sci USA.
104:5205–5210. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sanlioglu AD, Korcum AF, Pestereli E,
Erdogan G, Karaveli S, Savas B, Griffith TS and Sanlioglu S: TRAIL
death receptor-4 expression positively correlates with the tumor
grade in breast cancer patients with invasive ductal carcinoma. Int
J Radiat Oncol Biol Phys. 69:716–723. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
von Karstedt S, Montinaro A and Walczak H:
Exploring the TRAILs less travelled: TRAIL in cancer biology and
therapy. Nat Rev Cancer. 17:352–366. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sanlioglu AD, Dirice E, Elpek O, Korcum
AF, Ozdogan M, Suleymanlar I, Balci MK, Griffith TS and Sanlioglu
S: High TRAIL death receptor 4 and decoy receptor 2 expression
correlates with significant cell death in pancreatic ductal
adenocarcinoma patients. Pancreas. 38:154–160. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lalaoui N, Morlé A, Mérino D, Jacquemin G,
Iessi E, Morizot A, Shirley S, Robert B, Solary E, Garrido C and
Micheau O: TRAIL-R4 promotes tumor growth and resistance to
apoptosis in cervical carcinoma HeLa cells through AKT. PLoS One.
6:e196792011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sanlioglu AD, Dirice E, Aydin C, Erin N,
Koksoy S and Sanlioglu S: Surface TRAIL decoy receptor-4 expression
is correlated with TRAIL resistance in MCF7 breast cancer cells.
BMC Cancer. 5:542005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Labbé K, McIntire CR, Doiron K, Leblanc PM
and Saleh M: Cellular inhibitors of apoptosis proteins cIAP1 and
cIAP2 are required for efficient caspase-1 activation by the
inflammasome. Immunity. 35:897–907. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jiang XJ, Chen ZW, Zhao JF, Liao CX, Cai
QH and Lin J: cIAP2 via NF-κB signalling affects cell proliferation
and invasion in hepatocellular carcinoma. Life Sci. 266:1188672021.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Morrish E, Brumatti G and Silke J: Future
therapeutic directions for smac-mimetics. Cells. 9:4062020.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Beug ST, Conrad DP, Alain T, Korneluk RG
and Lacasse EC: Combinatorial cancer immunotherapy strategies with
proapoptotic small-molecule IAP antagonists. Int J Dev Biol.
59:141–147. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xu Y, Zhou L, Huang J, Liu F, Yu J, Zhan
Q, Zhang L and Zhao X: Role of Smac in determining the
chemotherapeutic response of esophageal squamous cell carcinoma.
Clin Cancer Res. 17:5412–5422. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Russo VC, Azar WJ, Yau SW, Sabin MA and
Werther GA: IGFBP-2: The dark horse in metabolism and cancer.
Cytokine Growth Factor Rev. 26:329–346. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yau SW, Azar WJ, Sabin MA, Werther GA and
Russo VC: IGFBP-2-taking the lead in growth, metabolism and cancer.
J Cell Commun Signal. 9:125–142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li T, Forbes ME, Fuller GN, Li J, Yang X
and Zhang W: IGFBP2: Integrative hub of developmental and oncogenic
signaling network. Oncogene. 39:2243–2257. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Rodriguez J, Herrero A, Li S, Rauch N,
Quintanilla A, Wynne K, Krstic A, Acosta JC, Taylor C, Schlisio S
and von Kriegsheim A: PHD3 regulates p53 protein stability by
hydroxylating proline 359. Cell Rep. 24:1316–1329. 2018. View Article : Google Scholar : PubMed/NCBI
|
